Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Halozyme Hypercon Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently handled by 1 distinct examiner and 1 distinct art unit, showing a narrow administrative scope for the company's pending matters. This structure suggests that the company's current patent efforts are focused on a specific pharmaceutical or biotechnological innovation that falls under the jurisdiction of 1 art unit. This status indicates the company's immediate administrative focus is highly centralized.
The busiest examiner for the portfolio is DIBRINO, MARIANNE, who is overseeing 1 pending office action. Since DIBRINO, MARIANNE is the only examiner with an active action, the company's immediate progress in the Biotechnology & Pharmaceuticals field depends entirely on this individual's review. The presence of only 1 distinct examiner and 1 distinct art unit means that the prosecution strategy can be highly tailored to the specific preferences and historical actions of the assigned examiner. This focus allows for a direct response to the current matter currently on record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344142 | Particle Formation And Morphology | DIBRINO, MARIANNE | 18d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18344142 | Particle Formation And Morphology | DIBRINO, MARIANNE | 1641 | §112Other | Final Rejection | 18d overdue | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial